Abbott Laboratories (ABT) Payables (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Payables data on file, last reported at $5.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 10.16% year-over-year to $5.8 billion; the trailing twelve-month figure through Mar 2026 stood at $5.8 billion (up 10.16% YoY), and the FY2025 full-year result was $5.3 billion, up 2.26% from the prior year.
• Payables advanced to $5.8 billion in Q1 2026, from $5.3 billion in the prior quarter.
• In the past five years, Payables ranged from a high of $5.8 billion in Q1 2026 to a low of $4.8 billion in Q3 2023.
• A 5-year average of $5.2 billion and a median of $5.2 billion in 2024 frame the typical range for Payables.
• Across the five-year window, Payables climbed 10.17% in 2022 and declined 9.42% in 2023, its largest moves.
• Tracing ABT's Payables over 5 years: stood at $5.5 billion in 2022, then decreased by 4.44% to $5.2 billion in 2023, then slipped by 0.59% to $5.2 billion in 2024, then gained by 2.26% to $5.3 billion in 2025, then increased by 8.28% to $5.8 billion in 2026.
• Business Quant data shows ABT's Payables at $5.8 billion in Q1 2026, $5.3 billion in Q4 2025, and $5.2 billion in Q3 2025.